Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
| ▸ | RBP4 | P02753 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9248509 | 0.86 | LMNA (0.60) | CDK5CDK5R1RBP4KLKB1KDM5A | |
| SCHEMBL4735220 | 0.85 | RBP4 (0.51) | CDK5CDK5R1RBP4KLKB1KDM5A | |
| SCHEMBL10567713 | 0.83 | MEN1 (0.60) | RBP4KDM4CMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16690901 | 0.83 | RBP4 (0.54) | CDK5CDK5R1RBP4KLKB1KDM5A | |
| SCHEMBL3688462 | 0.83 | KDM4C (0.57) | CDK5CDK5R1RBP4KLKB1KDM5A | |
| SCHEMBL18377475 | 0.82 | KLKB1 (0.56) | CDK5CDK5R1RBP4KLKB1KDM5A | |
| SCHEMBL554255 | 0.82 | KLKB1 (0.56) | CDK5CDK5R1KLKB1GRM2MEN1 | |
| SCHEMBL10571866 | 0.82 | MEN1 (0.46) | KLKB1KDM5AKDM4CKDM5BGRM2 | |
| SCHEMBL24094049 | 0.82 | KLKB1 (0.55) | CDK5CDK5R1RBP4KLKB1KDM5A | |
| SCHEMBL1775282 | 0.81 | HMOX1 (0.46) | GRM2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230104200-A1 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2023-04-06 | — | — | US | disclosed |
| EP-4153572-A1 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| CN-115667223-A | Imidazolium reagents for mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-112979660-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-111269221-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-107849023-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | CDK5 3073/4885CDK5R1 1200/4885RBP4 4866/4885 |
| US-20230104200-A1 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | SRMS, IPO4, PTMS | CDK5 522/4885CDK5R1 1157/4885RBP4 1615/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | CDK5 3073/4885CDK5R1 1200/4885RBP4 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.